文献速递神经肿瘤

点/反点:Dordaviprone治疗弥漫性中线胶质瘤——里程碑式批准还是过早之举?

Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
PubMed 文献 · Neuro Oncol · 2026-01-01

美国FDA基于早期单臂研究加速批准dordaviprone用于进展性H3 K27M突变弥漫性中线胶质瘤,该病中位总生存仅11个月且无系统性治疗显示有意义的生存获益。本文以正反观点讨论该批准的科学、临床与监管背景,认为应视为有条件批准,仍需确证性试验验证获益。

要点

  • FDA加速批准dordaviprone用于进展性H3 K27M突变DMG,基于早期单臂研究的影像学和生物学缓解。
  • DMG中位总生存仅11个月,该批准是首个针对该病的系统性治疗监管认可。
  • 批准数据多来自非随机研究,对新诊断患者及DIPG、脊髓肿瘤的疗效尚不明确。

核心结论

  • dordaviprone的加速批准应视为有条件批准,是重要一步但需确证性证据。

研究设计与样本

  • 本文为点/反点社论,基于早期研究(ONC006、ONC013、ONC014、ONC016、ONC018)的整合分析讨论dordaviprone的加速批准。

主要发现

  • 早期研究整合分析显示dordaviprone在部分患者中产生可测量的影像学和生物学缓解。
  • DMG中位总生存仅11个月,尚无系统性治疗显示有意义的生存获益。
  • 批准数据多来自非随机研究,对新诊断患者及DIPG和脊髓肿瘤的疗效不明确。

关键数值与推荐

  • FDA加速批准dordaviprone(ONC201,ModeysoTM)用于进展性H3 K27M突变DMG患者。
  • 加速批准基于耐用客观缓解率等替代终点,并强制要求上市后研究确证获益。

临床怎么用

  • 临床应将dordaviprone视为有条件批准的治疗选择,关注确证性试验结果。
  • 该批准可能加速药物组合、生物标志物和更好临床试验的研究。

局限性

  • 批准依据主要为非随机早期研究,证据级别有限。
  • 对新诊断患者及DIPG、脊髓肿瘤等 Related tumors 的疗效尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse midline glioma (DMG) remains one of the most aggressive and uniformly fatal brain tumors, with a median overall survival (OS) of only 11 months and no systemic therapy yet demonstrating a meaningful survival benefit. Primarily affecting children and young adults, DMG represents an area of profound unmet clinical need where families and oncologists have faced decades of therapeutic stagnation. The recent accelerated approval by the United States (US) Food and Drug Administration (FDA) of dordaviprone (ONC201, ModeysoTM) for patients with progressive H3 K27M-altered DMG marks the first regulatory recognition of a systemic therapy for this devastating disease. The decision has generated both optimism and debate within the neuro-oncology community. For many, the approval symbolizes long-overdue progress and affirms that systemic agents can demonstrate activity in DMG. For others, it raises concerns over whether the current evidence base is sufficient to justify widespread clinical adoption. The accelerated approval pathways allow for earlier access to therapy for serious life-threatening conditions based on surrogate endpoints, such as durable objective response rates (ORRs), while mandating post-approval studies to confirm benefit. However, while approvals using data from single-arm trials can make promising therapies available to patients expeditiously, such exceptional approvals present challenges that must be carefully considered. In the case of dordaviprone, this mechanism was applied following an integrated analysis of early-phase studies (ONC006 (NCT02525692), ONC013 (NCT03295396), ONC014 (NCT03416530),1 ONC016 (NCT05392374), and ONC018 (NCT03134131))2 that demonstrated measurable radiographic and biological responses in a subset of patients. Here, we examine the scientific, clinical, and regulatory context of the dordaviprone approval through contrasting perspectives. We consider both the landmark nature of this decision and the potential risks of overinterpreting preliminary evidence, aiming to clarify what this approval means for current practice and for the future development of therapies in DMG and other brain tumors. The United States (US) Food and Drug Administration (FDA) recently granted accelerated approval to dordaviprone (ONC201, ModeysoTM) for patients with H3 K27M–altered diffuse midline glioma, a rare and aggressive brain tumor with very few treatment options. This Point/Counterpoint editorial discusses what this decision means for science, regulation, and patient care. Accelerated approval allows the FDA to make promising treatments available sooner for serious diseases based on early signs of benefit, such as tumor shrinkage or how long patients respond to treatment. However, additional studies are still required to confirm that the drug truly improves outcomes. In this case, the approval was based on early studies and expanded-access programs that showed the drug may help a subset of patients. Important questions remain. Most of the data used for approval came from non-randomized studies, and it is unclear how well the drug works in newly diagnosed patients or in related tumors such as diffuse intrinsic pontine glioma (DIPG) and spinal cord tumors. We argue that this approval should be seen as conditional, an important step that may speed up research on drug combinations, biomarkers, and better clinical trials, while still requiring strong evidence. The ongoing ACTION trial (NCT05580562) will be critical for confirming the benefit of the drug and guiding how it should be used in practice.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Khasraw M, Dun MD, Arrillaga-Romany I, et al. Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step? Neuro Oncol. 2026. PMID: 42172613. doi:10.1093/neuonc/noag117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。